This is an observational study of patients undergoing treatment with PegIntron and Rebetol for chronic hepatitis C in clinical practice in Belgium. Treatment will not be administered as part of the study. Safety parameters will be assessed retrospectively. Efficacy parameters, such as relapse rates and sustained virologic response rates, will be assessed prospectively. The objective of the study is to examine any associations between safety, virologic, histologic, demographic parameters and patient outcome (relapse rates and sustained virologic response rates).

Inclusion Criteria:

• Male and female adult (18 years or older) subjects for whom the treating physician has decided to start treatment with PegIntron® and Rebetol® and reaching the End-of-Treatment time point.
• For the prospective component, evidence of treatment response at EOT after a complete course of therapy as per SmPC.
• Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
• Subjects must be diagnosed with chronic hepatitis C (genotypes 1, 2, 3, 4, 5 or 6).
• Subjects must be free of any clinically significant disease that would interfere with study participation.

Exclusion Criteria:

• For prospective component of the study: patients not achieving End-of-Treatment response after a complete course of therapy as per SmPC.

Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.